ReviewAmerican journal of clinical dermatology2026
Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dermatologic Toxicities Induced by JAK Inhibitors.American journal of clinical dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing efficacy of oncological therapies has led to a rapidly growing population of cancer survivors, shifting clinical attention from acute treatment-related toxicities to long-term and late sequelae. Among these, dermatological sequelae represent some of the most visible and persistent consequences of cancer treatments and may significantly impair quality of life. Persistent alopecia, nail disorders, pigmentary alterations, chronic radiation-induced skin changes, scarring, vascular abnormalities, mucosal alterations, and secondary skin cancers may develop or persist long after treatment completion, acting as constant reminders of the cancer experience. These conditions are not only cosmetic; they may be associated with functional limitations, psychological distress, and altered body image, particularly in patients treated during childhood or adolescence. While the role of supportive oncodermatology during active cancer treatment is well established, structured dermatological care in the survivorship phase remains insufficiently developed. This narrative review provides a comprehensive overview of the main long-lasting dermatological adverse events associated with chemotherapy, radiotherapy, targeted therapies, immunotherapy, endocrine treatments, and hematopoietic stem cell transplantation. In addition, available restorative and corrective dermatological interventions are discussed, with a focus on improving long-term outcomes and patient well-being. Recognizing and managing dermatological sequelae is an essential component of modern survivorship care, and dermatologists should play a central role in multidisciplinary follow-up programs dedicated to cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.